By: IPP Bureau
Last updated : February 06, 2025 11:17 am
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
JB Chemicals & Pharmaceuticals Ltd (JB Pharma), one of the fastest growing pharmaceutical companies in India, recorded revenue of Rs. 963 crores in the third quarter of FY25 registering growth of 14% from Rs. 845 crores in Q3 FY24.
Operating EBITDA (Earnings before Interest Depreciation and Taxes) improved by 15% to Rs. 270 crores. Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24.
Commenting on the financial results, Nikhil Chopra, CEO and Wholetime Director, JB Pharma said, “JB has delivered consistent growth over the last few years even amidst a volatile macroeconomic environment. This has been enabled by our mix of businesses and markets, specifically our focus on India branded formulations, CDMO, and select international markets which play to our strengths, with limited revenues in countries that might present trade-related or economic volatility challenges. JB is well-positioned to deliver continued growth going forward as well. The strategy and levers are well-defined, and we have a strong team that will execute."
"Our India business continues to drive market-beating growth led by chronic business and progressive portfolio within the acute segment. Our export business continues to be steady with sequential improvement witnessed in our CDMO business. While the growth run-rate of JB’s quarterly performance has been maintained, we have also improved our operating margins driven by product mix and efficiency initiatives. Advancement of various new projects in the CDMO business will flow through into growth numbers in the near to medium term, and we have a good pipeline of future product commercialization opportunities in international business which will deliver continued growth,” added Chopra.